Like most websites The Analytical Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Fields & Applications Mass Spectrometry, Metabolomics & Lipidomics, Clinical

Move Out of the Tunnel… and Into the Light!

I believe metabolomics has the potential to shed light onto the pathophysiology behind glaucomatous damage, as well as providing potential biomarkers for early glaucoma detection.

Influenced by both genetic and environmental factors, the metabolite profile gives us a “fingerprint” of the health status of the organism at the time of sampling. But aside from disease mechanisms and biomarkers, this technology has also been increasingly used for drug target discovery and the prediction of drug effects – and it can help move medical care towards a more personalized approach.

For all of these reasons, metabolomics is becoming widely used across different fields, from cancer research to obstetrics - and my own field of ophthalmology.

For all of these reasons, metabolomics is becoming widely used across different fields, from cancer research to obstetrics – and my own field of ophthalmology – where it keeps proving its value. A recent paper has shown the potential of metabolomics for the diagnosis of age-related macular degeneration (AMD); both the presence and stages of the disease could be distinguished by identifying differences in metabolic profiles in controls and patients with AMD (1). Glaucoma (the leading world cause of irreversible blindness (2)) is also a good candidate for metabolomic analysis, which has the potential to break knowledge barriers, driving us towards new treatments and personalized care. Our research group, led by Ingeborg Stalmans, recently reviewed results that have already been delivered by metabolomics in terms of understanding the pathophysiological processes of glaucoma in a clinical setting (3). Only one metabolome-wide study for glaucoma has been published to date; it identified significant metabolic differences in blood plasma samples from patients with primary open-angle glaucoma (POAG) and samples from healthy controls (4).

Metabolomics will help bring glaucoma care into a new era.

We feel that we can push this research a step further, so we are collecting blood, urine and aqueous humor samples from patients with POAG who are undergoing surgery (MISO Study; NCT03098316). All samples will be analyzed using mass spectrometry and nuclear magnetic resonance spectroscopy, and compared with control samples (from patients with cataract and no other eye disease). As metabolomics provides an overview of whole-body metabolism, we are also including a study group of patients with normal-tension glaucoma (NTG), since systemic vascular dysregulation is thought to play an important role in the pathogenesis in this group of patients.

In my view, metabolomics will help bring glaucoma care into a new era by reducing the numbers of patients arriving in our office already at an advanced stage of disease, and by revealing new research paths that can be used to develop new drugs and improve ophthalmic care.

Receive content, products, events as well as relevant industry updates from The Analytical Scientist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. I Laíns et al., “Human plasma metabolomics in age-related macular degeneration (AMD) using nuclear magnetic resonance spectroscopy”, PLoS One, 12, e0177749 (2017). PMID: 28542375.
  2. YC Tham et al., “Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis”, Ophthalmology, 121, 2081–2090 (2014). PMID: 24974815.
  3. J Barbosa-Breda et al., “Clinical metabolomics and glaucoma”, Ophthalmic Res, [Epub ahead of print], (2017). PMID: 28858875.
  4. LG Burgess et al., “Metabolome-wide association study of primary open angle glaucoma”, Invest Ophthalmol Vis Sci, 56, 5020–5028 (2015). PMID: 26230767.
About the Author
João Barbosa-Breda

João Barbosa-Breda is a Glaucoma Fellow, at the Ophthalmology Research Group of the KU Leuven (University of Leuven), Belgium.

Related Application Notes
Analytical Solutions for Analysis of Polymer Additives

| Contributed by Shimadzu

Characterization of MAbs Using FcR-Affinity and HILIC-MS

| Contributed by Tosoh

A Fast and Robust GC/MS/MS Analysis of 203 Pesticides in 10 Minutes in Spinach

| Contributed by Agilent Technologies

Related Product Profiles
Higher Peaks – Clearly.

| Contributed by Shimadzu Europa

Compact with countless benefits

| Contributed by Shimadzu Europa

The fine Art of Method Development

| Contributed by Shimadzu Europa

Register to The Analytical Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine